In conclusion, our data suggest that the combination therapy of cisplatin and TRAIL is a promising strategy for treating neuroblastoma that is controlled by the expression of N‐myc and caspase‐8, and its use may provide important information for the development of additional potential therapeutic strategies to fight neuroblastoma. This evidence concerns the gene MYCN and neuroblastoma.